This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Orot | |
|---|---|
| Name | Orot |
| Type | Concept |
Orot Orot is a term encountered across multiple domains including chemistry, biochemistry, medicine, literature, and cultural history. It commonly denotes the conjugate base of orotic acid and related salts or derivatives used in nutritional, clinical, and biochemical contexts. The term appears in biochemical pathways, clinical supplements, historical pharmaceutical formulations, and in literary or toponymic references that intersect with scientific discourse.
The name derives from orotic acid, itself named in early organic chemistry literature that overlapped with the researchers who characterized pyrimidine biosynthesis. Historical chemical literature connects the term to figures and institutions such as Friedrich Wöhler, Justus von Liebig, Louis Pasteur, Royal Society, and Académie des Sciences where early organic acid nomenclature and structural theories were debated. Nomenclature discussions later engaged groups including the International Union of Pure and Applied Chemistry and publications in journals like Journal of the American Chemical Society, Nature, and Proceedings of the National Academy of Sciences. The term has been adopted into pharmacopoeias overseen by bodies such as the United States Pharmacopeia and the European Pharmacopoeia where systematic naming conventions for salts and complexes are standardized.
In biochemical contexts, orotic acid and its salts are integral to pyrimidine nucleotide metabolism involving enzymes and pathways documented alongside entities like Carbamoyl phosphate synthetase II, Aspartate transcarbamylase, Dihydroorotase, Dihydroorotate dehydrogenase, and Orotidine 5'-phosphate decarboxylase. These enzymes appear in metabolic maps with metabolites such as carbamoyl phosphate, carbamoyl aspartate, dihydroorotate, orotidine monophosphate, uridine monophosphate, and cytidine triphosphate. Studies of pyrimidine biosynthesis reference model organisms and systems including Escherichia coli, Saccharomyces cerevisiae, Homo sapiens, Arabidopsis thaliana, and Drosophila melanogaster. Research on nucleotide salvage and de novo synthesis also intersects with signaling and replication pathways studied in contexts like DNA replication, RNA polymerase II, Ras signaling pathway, mTOR signaling pathway, and cellular processes characterized in cell lines such as HeLa cells and HEK 293.
Clinically, compounds described as orotates have been evaluated in contexts involving cardiology, hematology, and metabolic disorders. Trials and reports published in outlets like The Lancet, Journal of the American Medical Association, New England Journal of Medicine, and British Medical Journal have discussed formulations alongside interventions by institutions such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, and Karolinska Institutet. Investigations have compared orotate salts to chelated mineral complexes used in formulations prepared by pharmaceutical companies and compounding pharmacies regulated by agencies including the Food and Drug Administration and the European Medicines Agency. Clinical endpoints in studies reference conditions cataloged by organizations like World Health Organization, including discussions of anemia, cardiac ischemia, and metabolic enzyme deficiencies. Genetic disorders influencing pyrimidine pathways, such as Orotic aciduria and mutations in UMPS (uridine monophosphate synthase), are described in reviews and case reports appearing in genetics resources like Online Mendelian Inheritance in Man and specialty journals in human genetics and metabolic disorders.
Beyond laboratory and clinic, the term has surfaced in cultural, literary, and historical records where scientific language intersects with broader narratives. Historical pharmaceutical compendia from publishers associated with Elsevier, Springer, and Wiley include entries that trace adoption of orotate-containing preparations in 20th-century therapeutics. Public discourse and reportage by media outlets such as The New York Times, BBC News, and The Guardian have occasionally featured reporting on nutritional supplements and debated claims tied to mineral orotate products marketed by nutraceutical firms and retail chains like Walgreens and CVS Health. Academic histories of science tie the emergence of organometallic and organic acid therapeutics to laboratory cultures at institutions such as University of Oxford, Harvard University, University of Cambridge, Imperial College London, and University of Paris.
Chemical synthesis pathways for orotic acid and orotate salts are described in methods literature and patents filed with offices such as the United States Patent and Trademark Office and the European Patent Office. Preparative chemistry references include classical techniques appearing in volumes like Organic Syntheses and manuals used by industrial groups at companies such as BASF, Bayer, and Pfizer. Natural occurrence and biosynthetic formation of orotic intermediates are observed in microbes, plants, and animals studied in field and laboratory settings documented by researchers affiliated with Smithsonian Institution, Salk Institute, and national research labs like Lawrence Berkeley National Laboratory. Analytical detection and quantification employ technologies and instruments from manufacturers such as Agilent Technologies, Thermo Fisher Scientific, and Waters Corporation, using methods including high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance spectroscopy, and enzymatic assays standardized by organizations like Clinical and Laboratory Standards Institute.